Drug Discovery World (DDW), the Quarterly Business Review of Drug Discovery & Development

LATEST ISSUE: SPRING 2017 Archive

The Discoverome, creative destruction of barriers for faster to patient medicines R&D

By Chris Molloy

Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.

Pharma Derisking, approaches to reduce liability to major metabolically-driven causes of drug attrition

By Guy Webber

Intelligent application of early in vitro testing can help mitigate major drug development risks.

Spheroids rapidly becoming a preferred 3D culture format

By Dr John Comley

There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture.

Something old, something new... a marriage of technologies for immuno-oncology in vivo studies

By Dr Philip Dube

Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation.

Three-dimensional cell culture: a rapidly emerging technique for drug discovery

By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen

Past decades have witnessed significant efforts toward the development of 3D cell cultures. They are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.

Immuno-Oncology's Biomarker Dilemma - How to add value in an uncertain development landscape

By Dr Rachel Laing and Olivier Lesueur

Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies.

Monitoring the balance between immune repression and stimulation in cancer immunotherapy

By Dr Peter Schulz-Knappe and Dr Georg Lautscham

Cancer remains one of the main causes of death worldwide, yet recent strides have been made in the form of new cancer immunotherapies.

Horizon Discovery introduces four BRAF resistant melanoma PDX models

Horizon has announced it has added four BRAF-resistant melanoma PDX (patient derived xenograft) models to its range of commercially available in vivo models to support drug efficacy studies.

Owlstone Medical Establishes Scientific Advisory Board with Appointment of Professor Sir Bruce Ponder

Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced the appointment of Professor Sir Bruce Ponder FRCP FMedSci FRS to its newly established Scientific Advisory Board (SAB).

Merck Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes

Merck, today took a significant step toward increasing manufacturing flexibility and enabling higher productivity with the launch of the EX-CELL Advanced HD Perfusion Medium.

Irvine Scientific Launches New Xeno-free Medium for Hematopoietic Progenitor Cell Culture

Irvine has announced an addition to its products supporting stem & immunological cell therapies, with the introduction of PRIME-XV Hematopoietic Cell Basal Medium.

Gyros Protein Technologies introduces next generation Gyrolab Protein A Kit for Biotherapeutics

Gyros Protein Technologies AB has announced it has launched a new version of its Gyrolab Protein A Kit.

Avacta announces key Affimer patent to be granted in China

Avacta Group plc is pleased to announce that the principal patent protecting the Affimer technology has been accepted for grant in the Peopleâs Republic of China.

	Drug Discovery	Business	Chemistry	Enabling Technologies
	Informatics	Personalised Medicine	Screening	Therapeutics

	SpectraMax i3 Multi-Mode Detection System See how you can do more with your microplate reader than you ever imagined.

	Bioanalysis of Oxytocin Ultrasensitive Quantification Assay for Oxytocin in Human Plasma Using an LC/MS Microfluidics Platform